...
首页> 外文期刊>The American Journal of Medicine >Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum
【24h】

Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum

机译:非发酵革兰氏阴性菌的耐药性:最大耐药性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Nonfermenting gram-negative bacteria pose a particular difficulty for the healthcare community because they represent the problem of multidrug resistance to the maximum. Important members of the group in the United States include Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas mqlto-philia, and Burkholderia cepacia. These organisms are niche pathogens that primarily cause opportunistic healthcare-associated infections in patients who are critically ill or immunocompromised. Multidrug resistance is common and increasing among gram-negative nonfermenters, and a number of strains have now been identified that exhibit resistance to essentially all commonly used antibiotics, including anti-pseudomonal penicillins and cephalosporins, aminoglycosides, . tetracy dines, fluoroquinolones, tri-methoprim-sulfamethoxazole, and carbapehems. Polymyxins are the remaining antibiotic drug class with fairly consistent activity against multidrug-resistant strains of P aeruginosa, Acinetobacter spp, and Smaltophilia. However, most multidrug-resistant B cepacia are not susceptible to polymyxins, and systemic polymyxins carry the risk of nephrotoxicity for all patients treated with these agents, the elderly in particular. A variety of resistance mechanisms have been identified in P aeruginosa and other gram-negative nonfermenters, including enzyme production, overexpression of efflux pumps, porin deficiencies, and target-site alterations. Multiple resistance genes frequently coexist in the same organism. Multidrug resistance in gram-negative nonfermenters makes treatment of infections caused by these pathogens both difficult and expensive. Improved methods for susceptibility testing are needed when dealing with these organisms, including emerging strains expressing metallo-beta-lactamases. Improved antibiotic stewardship and infection-control measures will be needed to prevent or slow the emergence and spread of multidrug-resistant, nonfermenting gram-negative bacilli in the healthcare setting
机译:非发酵革兰氏阴性细菌给医疗保健界带来了特别的困难,因为它们代表了最大程度的多药耐药性问题。该小组在美国的重要成员包括铜绿假单胞菌,鲍曼不动杆菌,嗜性嗜单胞菌和洋葱伯克霍尔德菌。这些生物是利基病原体,主要在重症患者或免疫功能低下的患者中引起机会性的医疗保健相关感染。在革兰氏阴性非发酵菌中,多药耐药是常见的并且正在增加,并且现已鉴定出许多菌株,它们对基本上所有常用的抗生素都表现出耐药性,包括抗假性青霉素和头孢菌素,氨基糖苷类。四环二烯,氟喹诺酮类,三甲氧苄氨磺胺甲基异恶唑和羧甲基纤维素。多粘菌素是其余的抗生素类药物,对铜绿假单胞菌,不动杆菌属和嗜血菌的多重耐药菌株具有相当稳定的活性。但是,大多数具有多重耐药性的洋葱伯克西汀对多粘菌素均不敏感,全身性多粘菌素对所有使用这些药物治疗的患者(尤其是老年人)都具有肾毒性的风险。在铜绿假单胞菌和其他革兰氏阴性非发酵菌中已鉴定出多种耐药机制,包括酶产生,外排泵过表达,孔蛋白缺乏和靶位改变。多个抗性基因经常共存于同一生物中。革兰氏阴性非发酵罐中的多药耐药性使得治疗由这些病原体引起的感染既困难又昂贵。处理这些生物(包括表达金属β-内酰胺酶的新兴菌株)时,需要改进的敏感性测试方法。在医疗机构中,将需要改善抗生素管理和感染控制措施,以防止或减慢多重耐药,非发酵革兰氏阴性杆菌的出现和传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号